blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2881111

EP2881111 - IMMUNE CELL ACTIVATION INHIBITOR AND USE THEREOF [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  21.07.2017
Database last updated on 18.10.2024
FormerExamination is in progress
Status updated on  14.04.2017
Most recent event   Tooltip21.07.2017Withdrawal of applicationpublished on 23.08.2017  [2017/34]
Applicant(s)For all designated states
Ehime University
10-13, Dogohimata Matsuyama-shi
Ehime 790-8577 / JP
[2015/24]
Inventor(s)01 / TANAKA, Junya
c/o Ehime University
Graduate School of Medicine
Shitsukawa
Toon-shi Ehime 791-0295 / JP
 [2015/24]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2015/24]Tuxworth, Pamela M.
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date13826292.802.08.2013
WO2013JP71028
Priority number, dateJP2012017340503.08.2012         Original published format: JP 2012173405
[2015/24]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014021455
Date:06.02.2014
Language:JA
[2014/06]
Type: A1 Application with search report 
No.:EP2881111
Date:10.06.2015
Language:EN
[2015/24]
Search report(s)International search report - published on:JP06.02.2014
(Supplementary) European search report - dispatched on:EP18.11.2015
ClassificationIPC:A61K31/17, A61P25/00, A61P25/16, A61P25/28, A61P29/00, A61P31/04, A61P37/06
[2015/24]
CPC:
A61K31/17 (EP,US); A61P17/00 (EP); A61P17/02 (EP);
A61P17/04 (EP); A61P17/06 (EP); A61P17/08 (EP);
A61P25/00 (EP); A61P25/16 (EP); A61P25/28 (EP);
A61P29/00 (EP); A61P31/04 (EP); A61P37/06 (EP);
A61P37/08 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/24]
TitleGerman:IMMUNZELLENAKTIVIERUNGSHEMMER UND SEINE VERWENDUNG[2015/24]
English:IMMUNE CELL ACTIVATION INHIBITOR AND USE THEREOF[2015/24]
French:INHIBITEUR DE L'ACTIVATION D'UNE CELLULE IMMUNITAIRE ET SON UTILISATION[2015/24]
Entry into regional phase03.03.2015Translation filed 
03.03.2015National basic fee paid 
03.03.2015Search fee paid 
03.03.2015Designation fee(s) paid 
03.03.2015Examination fee paid 
Examination procedure29.01.2014Request for preliminary examination filed
International Preliminary Examining Authority: JP
03.03.2015Examination requested  [2015/24]
06.06.2016Amendment by applicant (claims and/or description)
13.04.2017Despatch of a communication from the examining division (Time limit: M04)
19.07.2017Application withdrawn by applicant  [2017/34]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.04.2017
Fees paidRenewal fee
10.08.2015Renewal fee patent year 03
11.08.2016Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]JP2004231546  (TAISHO PHARMA CO LTD) [X] 1,8,12,13 * abstract * * paragraph [0010] * * paragraph [0012] *;
 [X]JP4787499B  (KOWA CO) [X] 1,8,12,13 * examples 3,8 *;
 [X]US5409709  (OZAWA KIYOTAKA [JP], et al) [X] 1,8,12,13 * abstract *;
 [X]UA61135  (INST PHARM & TOXICOLOGY AMMS [UA]) [X] 12,13 * abstract *;
 [E]EP2702989  (KOWA CO [JP]) [E] 8 * abstract *
 [XI]  - CHUN-YA KUO ET AL, "Psychosis associated with bromvalerylurea abuse in a patient with traumatic brain injury", GENERAL HOSPITAL PSYCHIATRY., US, (20120501), vol. 34, no. 3, doi:10.1016/j.genhosppsych.2011.10.010, ISSN 0163-8343, pages e3 - e4, XP055227682 [X] 8 * the whole document * [I] 12,13,15

DOI:   http://dx.doi.org/10.1016/j.genhosppsych.2011.10.010
 [I]  - JIUN-NONG LIN ET AL, "Myoclonic jerks due to acute bromovalerylurea intoxication", CLINICAL TOXICOLOGY, US, (20080101), vol. 46, no. 9, doi:10.1080/15563650802020361, ISSN 1556-3650, pages 861 - 863, XP055227742 [I] 12-15 * the whole document *

DOI:   http://dx.doi.org/10.1080/15563650802020361
International search[X]JPH11139971  (SANKYO CO);
 [Y]WO03077832  (PHARMOS CORP [US], et al);
 [A]WO2009001356  (YISSUM RES DEV CO [IL], et al);
 [XP]  - TASUKU NISHIHARA ET AL., "Bromovalerylurea wa Macrophage no Kasseika o Yokusei shi, Haiketsusho ni Taisuru Chiryo Koka o Motsu", JOURNAL OF THE PHYSIOLOGICAL SOCIETY OF JAPAN 0031-9015, (201303), vol. 75, no. 2, page 74, XP008176656
 [XP]  - HITOMI AONO ET AL., "Kotenteki na Chinsei Saimin'yaku Bromovalerylurea no Parkinson-byo Chiryoyaku to shite no Kanosei", JOURNAL OF THE PHYSIOLOGICAL SOCIETY OF JAPAN 0031-9015, (201303), vol. 75, no. 2, page 73, XP008176657
by applicant   - HIDEKI MOCHIZUKI, "Rinsho Shinkei-gaku", PARKINSON BYOU NO CHIRYOU TO BYOUTAI, (2010), vol. 50, pages 623 - 627
    - KUMAR, A. ET AL., "A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study", CRITICAL CARE MEDICINE, (2011), vol. 38, pages 1651 - 1664
    - PIERACCI, F. M.; BARIE, P. S., "Management of severe sepsis of abdominal origin", SCANDINAVIAN JOURNAL OF SURGERY, (2007), vol. 96, pages 184 - 196
    - BALLARD, C ET AL., ALZHEIMER'S DISEASE. LANCET, (2011), vol. 377, pages 1019 - 1031
    - CHOUDHURY ET AL., BRAIN AND BEHAVIOR, (2011), vol. 1, pages 26 - 43
    - MATSUMOTO ET AL., JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM, (2008), vol. 28, pages 149 - 163
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.